Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01188733

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis

Sponsor: Mayo Clinic

Conditions Cirrhosis Esophageal Varices Portal Hypertension

Interventions Long acting Octreotide 30mg Long acting octreotide 10mg Saline

Updated 5 times since 2017 Last updated: Aug 24, 2010 Started: Jun 30, 1998 Primary completion: Jul 31, 2000 Completion: Dec 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Cirrhosis and Esophageal Varices, this trial is completed. The trial is conducted by Mayo Clinic and has accumulated 5 data snapshots since 1998. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jun 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.